List view / Grid view
7 February 2014 | By kdm communications
Quotient Clinical has commenced its 50th RapidFACT (Rapid Formulation development And Clinical Testing) program – a significant milestone in the development of this service...
6 February 2014 | By AstraZeneca
"As expected, our financial performance for 2013 reflects the ongoing impact from the loss of exclusivity for several key brands..."
5 February 2014 | By European Medicines Agency
A total of 11 out of 81 medicines recommended for marketing authorisation by the European Medicines Agency’s Committee for Medicinal Products for Human Use in 2013 were intended for the treatment of rare diseases...
5 February 2014 | By Pfizer
Agreement to combine Merck’s investigational anti-PD-1 and key Pfizer oncology assets...
5 February 2014 | By Amgen
Amgen and Merck announced that they have entered into an agreement through a subsidiary to evaluate the safety and efficacy of talimogene laherparepvec...
3 February 2014 | By Pfizer
Clinical benefit demonstrated for potential first-in-class CDK 4 and 6 inhibitor...
3 February 2014 | By Biogen Idec
Biogen Idec to begin launching TECFIDERA in initial EU Countries in the coming weeks...
3 February 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the FDA has granted Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for the treatment of cytopenias...
3 February 2014 | By AstraZeneca
AstraZeneca announced that it completed, on 1 February 2014, the acquisition of the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance...
31 January 2014 | By Suven Life Sciences Ltd
Suven announces that the grant of three product patents one each from Canada, China and India corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through through 2025...
31 January 2014 | By Edison Pharmaceuticals
Novel partnership in drugs targeting biological energy...
31 January 2014 | By AbbVie
AbbVie announced the completion of its phase III clinical program and released results of four additional studies designed to assess AbbVie's investigational all-oral, interferon-free therapy...
30 January 2014 | By Roche
Roche’s CEO Severin Schwan: “2013 was a very good year for Roche. We exceeded our financial targets with strong demand for our existing products and positive uptake of recently launched medicines and diagnostics...
30 January 2014 | By Biogen Idec
Relationship leverages UCB’s expertise and presence in Asia to bring Biogen Idec’s Innovative therapies to patients in new markets...
30 January 2014 | By Amgen
RUTHERFORD-2 study meets co-primary endpoints of ldl cholesterol reduction Amgen also announces results from phase 3 study with automated mini-doser completion of fifth phase 3 study forms basis for global filing plan...
